Discovers, develops, and commercializes polyclonal antibodies for human health. Operates in two segments: Research and Development, and Hyperimmune Products. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 77% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 68% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 77% a year on average.
Sales run at $5.4M a year. A small number, but proof the product has real buyers.
A loss of $2.7M against $5.4M in annual sales.
At the current pace of spending, the cash lasts about 2.4 years. After that, the company needs to find new money.
On our five-subject report card, IMRN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IMRN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.